Are Drug Prices Too Low?

In the following video, Motley Fool health-care bureau chief Brenton Flynn discusses one criticism made by Eli Lilly (NYSE: LLY  ) CEO John Lechleiter of a problem facing big pharmaceutical companies in Europe: Drugs are too cheap. He specifically focuses on how differences in European health-care systems vs. those in the United States mean a lot of pressure to lower prices on pharmaceuticals in Europe, which is damaging to the industry.

Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities, and reasons to buy and sell today. To find out more click here to claim your copy today.



Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2300257, ~/Articles/ArticleHandler.aspx, 4/21/2014 3:39:46 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement